KURA Kura Oncology, Inc. Stock Quote

KURA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.64	Insider Own	0.10%	Shs Outstand	56.41M	Perf Week	-12.90%
Market Cap	2.19B	Forward P/E	-	EPS next Y	-1.97	Insider Trans	-90.88%	Shs Float	50.85M	Perf Month	-15.16%
Income	-81.30M	PEG	-	EPS next Q	-0.45	Inst Own	84.80%	Short Float	9.97%	Perf Quarter	-0.41%
Sales	-	P/S	-	EPS this Y	12.40%	Inst Trans	1.74%	Short Ratio	5.95	Perf Half Y	95.13%
Book/sh	5.43	P/B	6.28	EPS next Y	-16.60%	ROA	-28.00%	Target Price	45.00	Perf Year	163.04%
Cash/sh	5.07	P/C	6.72	EPS next 5Y	19.93%	ROE	-31.00%	52W Range	6.35 - 43.00	Perf YTD	4.38%
Dividend	-	P/FCF	-	EPS past 5Y	-42.90%	ROI	-	52W High	-20.72%	Beta	1.96
Dividend %	-	Quick Ratio	15.20	Sales past 5Y	-	Gross Margin	-	52W Low	436.85%	ATR	2.39
Employees	83	Current Ratio	15.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.49	Volatility	6.21% 5.93%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-16.30%	Profit Margin	-	Rel Volume	0.83	Prev Close	34.65
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 05 BMO	Payout	-	Avg Volume	851.64K	Price	34.09
Recom	1.80	SMA20	-5.20%	SMA50	-7.35%	SMA200	39.26%	Volume	703,760	Change	-1.62%

Dec-07-20

Reiterated

H.C. Wainwright

Buy

$40 → $45

Dec-03-20

Initiated

Stifel

Buy

$45

Nov-05-20

Downgrade

Piper Sandler

Overweight → Neutral

Jul-07-20

Initiated

Credit Suisse

Outperform

$27

May-05-20

Initiated

Barclays

Overweight

$24

Jul-18-19

Initiated

Deutsche Bank

Buy

$28

Nov-09-18

Initiated

Piper Jaffray

Overweight

Aug-01-18

Initiated

H.C. Wainwright

Buy

$31

Oct-13-16

Resumed

Leerink Partners

Outperform

$15

Jan-22-16

Initiated

JMP Securities

Mkt Outperform

Dec-30-15

Initiated

Oppenheimer

Outperform

$16

Dec-16-15

Initiated

Citigroup

Buy

Jan-11-21 03:42PM	Illumina CEO Says Business Is Bouncing Back. The Gene Sequencer Sees New Opportunities. Barrons.com
Jan-07-21 07:30AM	Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference GlobeNewswire
Jan-06-21 07:30AM	Kura Oncology to Present at J.P. Morgan Healthcare Conference GlobeNewswire +10.06%
Dec-22-20 09:29AM	Is KURA A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-11-20 04:05PM	Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Dec-10-20 07:30AM	Kura Oncology to Participate in the JMP Securities Hematology Summit GlobeNewswire +5.99%
Dec-08-20 08:22PM	Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire +8.15%
Dec-07-20 04:01PM	Kura Oncology Announces Commencement of Public Offering of Common Stock GlobeNewswire
10:06AM	Here Are The Winners Of This Year's Biggest Blood Cancer Meeting Investor's Business Daily
Dec-05-20 12:30PM	Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting GlobeNewswire
Nov-24-20 07:30AM	Kura Oncology to Host Virtual Investor Event on December 5, 2020 GlobeNewswire
Nov-07-20 12:01AM	Kura Oncology, Inc. (KURA) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:30AM	Kura Oncology Reports Third Quarter 2020 Financial Results GlobeNewswire +6.59%
06:15AM	Kura Oncology, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences GlobeNewswire
Oct-29-20 07:30AM	Kura Oncology to Report Third Quarter 2020 Financial Results GlobeNewswire
Oct-26-20 07:30AM	Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3K Inhibitor in Head and Neck Squamous Cell Carcinoma GlobeNewswire
Oct-07-20 07:30AM	Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH GlobeNewswire +7.77%
Sep-15-20 12:21AM	Hedge Funds Never Been This Bullish On Kura Oncology, Inc. (KURA) Insider Monkey
Sep-08-20 07:30AM	Kura Oncology to Participate in Two Upcoming Investor Conferences GlobeNewswire +6.09%
Aug-26-20 01:33PM	Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
08:31AM	Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session Zacks
Aug-25-20 07:30AM	Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer GlobeNewswire +6.78%
Aug-06-20 04:05PM	Kura Oncology Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-04-20 07:30AM	Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-30-20 07:30AM	Kura Oncology to Report Second Quarter 2020 Financial Results GlobeNewswire
Jul-29-20 10:23AM	How Many Kura Oncology, Inc. (NASDAQ:KURA) Shares Do Institutions Own? Simply Wall St. -6.32%
Jul-17-20 10:37AM	Did Hedge Funds Make The Right Call On Kura Oncology, Inc. (KURA) ? Insider Monkey
Jun-16-20 10:46AM	Hedge Funds Arent Done Buying Kura Oncology, Inc. (KURA) Insider Monkey
Jun-11-20 07:30AM	Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum GlobeNewswire -9.17%
May-29-20 08:00AM	Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma GlobeNewswire
May-13-20 05:00PM	Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program GlobeNewswire
03:18AM	Edited Transcript of KURA earnings conference call or presentation 4-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-08-20 04:03PM	Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
May-07-20 07:30AM	Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020 GlobeNewswire
May-06-20 09:00AM	Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock GlobeNewswire
May-05-20 04:01PM	Kura Oncology Announces Commencement of Public Offering of Common Stock GlobeNewswire
11:30AM	Kura Oncology, Inc. (KURA) Q1 2020 Earnings Call Transcript Motley Fool
May-04-20 04:05PM	Kura Oncology Reports First Quarter 2020 Financial Results GlobeNewswire +5.91%
Apr-29-20 07:30AM	Kura Oncology to Report First Quarter 2020 Financial Results GlobeNewswire
Apr-28-20 03:09PM	Why Kura Oncology Is Skyrocketing Today Motley Fool +48.94%
Mar-10-20 03:18AM	Edited Transcript of KURA earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-03-20 07:30AM	Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas GlobeNewswire
Feb-25-20 04:03PM	Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-19-20 04:05PM	Kura Oncology to Participate in Three Upcoming Investor Conferences GlobeNewswire
Feb-18-20 04:05PM	Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Jan-24-20 10:44AM	The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study Benzinga
Jan-23-20 04:05PM	Kura Oncology Announces Transition of Chief Medical Officer GlobeNewswire
Jan-21-20 04:09AM	3 Healthcare Stocks That Can Double in the Next Year TipRanks
Jan-09-20 07:30AM	Kura Oncology to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-06-20 07:30AM	Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer GlobeNewswire
Dec-16-19 07:30AM	Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial GlobeNewswire
Dec-10-19 02:21PM	Kura Oncology, Inc. (KURA): Hedge Funds Cant Make Up Their Minds Insider Monkey
Dec-08-19 12:00PM	Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma GlobeNewswire
Nov-26-19 07:30AM	Kura Oncology to Participate in Piper Jaffray Healthcare Conference GlobeNewswire
Nov-25-19 05:51AM	Kura Oncology Requires Plenty of Patience by Investors TheStreet.com
Nov-15-19 04:29PM	Edited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 07:30AM	Kura Oncology to Present at Stifel Healthcare Conference GlobeNewswire
Nov-09-19 02:26PM	Hedge Funds Have Never Been This Bullish On Kura Oncology, Inc. (KURA) Insider Monkey
Nov-06-19 09:06AM	Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting GlobeNewswire
Nov-05-19 04:05PM	Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-19 07:30AM	Kura Oncology Appoints James Basta as Chief Legal Officer GlobeNewswire
Oct-30-19 07:30AM	Kura Oncology to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-29-19 11:50AM	Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer GlobeNewswire
Oct-23-19 04:05PM	Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Oct-16-19 04:30PM	Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Oct-15-19 07:30AM	Kura Oncology Expands Board of Directors with Appointment of Diane Parks GlobeNewswire
Oct-01-19 01:05AM	Edited Transcript of KURA earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-16-19 07:30AM	Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia GlobeNewswire
Sep-03-19 07:30AM	Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma GlobeNewswire
Aug-29-19 07:30AM	Kura Oncology to Participate in Two Upcoming Investor Conferences GlobeNewswire
Aug-12-19 04:05PM	Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer GlobeNewswire -5.51%
Aug-07-19 07:30AM	Kura Oncology to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-03-19 12:08AM	Kura Oncology, Inc. (KURA) 2019 Q2 Earnings Call Transcript Motley Fool
Jul-25-19 07:30AM	Kura Oncology to Report Second Quarter 2019 Financial Results GlobeNewswire
Jul-24-19 07:30AM	Kura Oncologys Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia GlobeNewswire
Jul-11-19 07:30AM	Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents GlobeNewswire
Jul-02-19 09:15AM	Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue? Zacks
Jun-23-19 08:50AM	Do Insiders Own Shares In Kura Oncology, Inc. (NASDAQ:KURA)? Simply Wall St.
08:48AM	What Kind Of Investor Owns Most Of Kura Oncology, Inc. (NASDAQ:KURA)? Simply Wall St.
Jun-21-19 04:30PM	Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Jun-18-19 11:31PM	Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock GlobeNewswire
04:01PM	Kura Oncology Announces Commencement of Public Offering of Common Stock GlobeNewswire
10:46AM	Is Kura Oncology, Inc. (KURA) A Good Stock To Buy? Insider Monkey
Jun-17-19 09:31AM	Company News For Jun 17, 2019 Zacks
Jun-14-19 10:03AM	Kura Oncology Soars After Lymphoma Treatment Test Results TheStreet.com
07:48AM	Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal MarketWatch
07:00AM	Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma GlobeNewswire
May-15-19 12:14PM	Edited Transcript of KURA earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 01:15PM	Heres What Hedge Funds Think About Kura Oncology, Inc. (KURA) Insider Monkey
May-07-19 08:49PM	Kura Oncology, Inc. (KURA) Q1 2019 Earnings Call Transcript Motley Fool
05:54PM	Kura Oncology: 1Q Earnings Snapshot Associated Press
04:05PM	Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones GlobeNewswire
Apr-30-19 07:30AM	Kura Oncology to Report First Quarter 2019 Financial Results GlobeNewswire
Apr-25-19 12:36PM	Edited Transcript of KURA earnings conference call or presentation 5-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Apr-02-19 04:04PM	Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications GlobeNewswire
Mar-29-19 07:10AM	Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-27-19 07:16AM	The Kura Oncology (NASDAQ:KURA) Share Price Has Soared 317%, Delighting Many Shareholders Simply Wall St.
Mar-06-19 07:30AM	Kura Oncology to Participate in Two Upcoming Investor Conferences GlobeNewswire -7.29%
Mar-05-19 07:13PM	Kura Oncology, Inc. (KURA) Q4 2018 Earnings Conference Call Transcript Motley Fool

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FORD KATHLEEN	Chief Operating Officer	Dec 15	Option Exercise	19.43	9,375	182,156	6,250	Dec 16 04:02 PM
FORD KATHLEEN	Chief Operating Officer	Dec 15	Sale	40.60	9,375	380,667	0	Dec 16 04:02 PM
WILSON TROY EDWARD	President and CEO	Dec 01	Option Exercise	6.15	11,855	72,908	39,951	Dec 02 04:04 PM
FORD KATHLEEN	Chief Operating Officer	Nov 10	Option Exercise	19.43	6,250	121,438	6,250	Nov 12 05:02 PM
FORD KATHLEEN	Chief Operating Officer	Nov 10	Sale	39.43	6,250	246,438	0	Nov 12 05:02 PM
WILSON TROY EDWARD	President and CEO	Oct 08	Option Exercise	6.15	50,370	309,776	78,466	Oct 08 06:55 PM
WILSON TROY EDWARD	President and CEO	Oct 08	Sale	34.00	106,736	3,629,024	0	Oct 08 06:55 PM
WILSON TROY EDWARD	President and CEO	Oct 08	Sale	34.00	50,370	1,712,580	28,096	Oct 08 06:55 PM
WILSON TROY EDWARD	President and CEO	Oct 07	Option Exercise	6.15	4,586	28,204	32,682	Oct 08 06:55 PM
WILSON TROY EDWARD	President and CEO	Oct 07	Sale	32.00	99,900	3,196,800	106,736	Oct 08 06:55 PM
WILSON TROY EDWARD	President and CEO	Oct 07	Sale	34.00	4,586	155,924	28,096	Oct 08 06:55 PM
WILSON TROY EDWARD	President and CEO	Oct 06	Sale	32.00	100	3,200	206,636	Oct 08 06:55 PM
FORD KATHLEEN	Chief Operating Officer	Sep 15	Option Exercise	19.43	6,250	121,438	6,250	Sep 15 07:25 PM
FORD KATHLEEN	Chief Operating Officer	Sep 15	Sale	29.43	6,250	183,938	0	Sep 15 07:25 PM
GRASSO MARC	CFO, CBO	Sep 14	Option Exercise	29.00	10,000	290,000	10,000	Sep 15 07:23 PM
FORD KATHLEEN	Chief Operating Officer	Sep 14	Option Exercise	19.43	6,250	121,438	6,250	Sep 15 07:25 PM
FORD KATHLEEN	Chief Operating Officer	Sep 14	Sale	29.43	6,250	183,938	0	Sep 15 07:25 PM
GRASSO MARC	CFO, CBO	Sep 14	Sale	29.00	10,000	290,000	0	Sep 15 07:23 PM
WILSON TROY EDWARD	President and CEO	Sep 14	Sale	28.82	98,490	2,838,876	206,736	Sep 15 07:22 PM
WILSON TROY EDWARD	President and CEO	Sep 11	Option Exercise	6.15	17,926	110,245	46,022	Sep 15 07:22 PM
WILSON TROY EDWARD	President and CEO	Sep 11	Sale	28.00	485	13,580	305,226	Sep 15 07:22 PM
WILSON TROY EDWARD	President and CEO	Sep 11	Sale	28.00	17,926	501,928	28,096	Sep 15 07:22 PM
WILSON TROY EDWARD	President and CEO	Sep 10	Option Exercise	6.15	37,030	227,735	65,126	Sep 10 06:05 PM
WILSON TROY EDWARD	President and CEO	Sep 10	Sale	28.00	1,025	28,700	305,711	Sep 10 06:05 PM
WILSON TROY EDWARD	President and CEO	Sep 10	Sale	28.00	37,030	1,036,840	28,096	Sep 10 06:05 PM
GRASSO MARC	CFO, CBO	Sep 08	Option Exercise	15.47	10,000	154,700	10,000	Sep 10 06:04 PM
WILSON TROY EDWARD	President and CEO	Sep 08	Sale	26.00	50,000	1,300,000	306,736	Sep 10 06:05 PM
GRASSO MARC	CFO, CBO	Sep 08	Sale	26.00	10,000	260,000	0	Sep 10 06:04 PM
WILSON TROY EDWARD	President and CEO	Aug 25	Option Exercise	6.14	23,053	141,486	51,149	Aug 26 06:24 PM
GRASSO MARC	CFO, CBO	Aug 25	Option Exercise	15.47	10,000	154,700	10,000	Aug 26 06:22 PM
GRASSO MARC	CFO, CBO	Aug 25	Sale	23.00	10,000	230,000	0	Aug 26 06:22 PM
WILSON TROY EDWARD	President and CEO	Aug 25	Sale	22.37	23,053	515,788	28,096	Aug 26 06:24 PM
WILSON TROY EDWARD	President and CEO	Aug 24	Option Exercise	4.80	6,568	31,526	34,664	Aug 26 06:24 PM
WILSON TROY EDWARD	President and CEO	Aug 24	Sale	22.04	6,568	144,770	28,096	Aug 26 06:24 PM
WILSON TROY EDWARD	President and CEO	Aug 19	Option Exercise	4.80	11,913	57,182	40,009	Aug 19 06:38 PM
WILSON TROY EDWARD	President and CEO	Aug 19	Sale	22.09	11,913	263,196	28,096	Aug 19 06:38 PM
WILSON TROY EDWARD	President and CEO	Aug 18	Option Exercise	4.80	521	2,501	28,617	Aug 19 06:38 PM
WILSON TROY EDWARD	President and CEO	Aug 18	Sale	22.00	521	11,462	28,096	Aug 19 06:38 PM
WILSON TROY EDWARD	President and CEO	Aug 17	Option Exercise	4.80	12,901	61,925	40,997	Aug 19 06:38 PM
WILSON TROY EDWARD	President and CEO	Aug 17	Sale	22.00	50,000	1,100,000	356,736	Aug 19 06:38 PM
WILSON TROY EDWARD	President and CEO	Aug 17	Sale	22.00	12,901	283,868	28,096	Aug 19 06:38 PM
GRASSO MARC	CFO, CBO	Aug 07	Option Exercise	15.47	7,102	109,868	10,000	Aug 11 05:02 PM
GRASSO MARC	CFO, CBO	Aug 07	Sale	20.00	10,000	200,000	0	Aug 11 05:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience